Creating better treatments for HIV-1 using capsid inhibitors
Development of Improved HIV-1 Capsid Inhibitors
This study is working on creating better versions of a new HIV-1 treatment called Lenacapavir to help people who have developed resistance to current medications, making it easier for them to manage their condition.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Ohio State University NIH-funded |
| Lab location | 1 site (Columbus, UNITED STATES) |
| Project ID | NIH-10759437 on NIH RePORTER |
What this research studies
This research focuses on developing improved versions of a new HIV-1 treatment called Lenacapavir, which targets the virus's capsid protein. The approach involves synthesizing different components of Lenacapavir in a modular way, allowing for modifications that could enhance its effectiveness and reduce the risk of drug resistance. By testing these new analogs in laboratory settings, the researchers aim to find more potent treatments for patients who have developed resistance to existing therapies. This work is crucial for improving the management of HIV-1, especially in patients with multi-drug resistant strains.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals living with HIV-1, particularly those who have experienced treatment failures or have multi-drug resistant strains.
Not a fit: Patients who are newly diagnosed with HIV-1 and have not yet undergone treatment may not benefit directly from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective HIV-1 treatments that are less likely to encounter resistance, improving health outcomes for patients.
How similar studies have performed: Previous research has shown promise with similar capsid-targeting approaches, indicating potential for success in this area.
Where this research is happening
Columbus, UNITED STATES
- Ohio State University — Columbus, United States (Active)
Researchers
- Principal investigator: Adu-Ampratwum, Daniel — Ohio State University
- Study coordinator: Adu-Ampratwum, Daniel
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.